关于美国《罕见病药物法案》(OrphanDrugAct),表述正确的是: A. 1983年通过 B. 罕见性疾病是指患者人数不超过200,000人的疾病 C. 该法案规定
Carolina:The University of North Carolina at Chapel Hill,2009:1.Redington L. The Orphan Drug Act of 1983:a case study of issue framing and the failure to effect policy change from 1990-1994[R].Department of Health Policy and Management,School of Public Health,2009.30-36....
Patient populations eligible for orphan designation have shifted and evolved during the nine years since the enactment of the Orphan Drug Act; the size of populations with orphan diseases keeps changing. In the early days of orphan drug development, prevalence figures were very small ones. In 1983...
罕见病药物又称为“孤儿药”( orphan drug) ,包括药物、疫苗及诊断试剂,用于预防、诊断或治疗罕见病。美国于1983年颁布《孤儿药法案》( Orphan Drug Act,ODA) [3],逐步建立鼓励罕见病药物研发的长效机制。ODA 实施37 年以来,美国罕见病药物研发和审批取得突破性进展。本文主要通过对美国罕见病药物临床试验、资格认...
but some drug companies have been accused of abusing the law's provisions by making inordinately high profits on orphan drugs under monopoly. Since the 1983 act went into effect, many orphan drugs have been approved, including those for the treatment of such conditions asAIDS,cystic fibrosis, ...
1983年1月4日美国国会通过的美国《罕见病药物法》(Orphan Drug Act)是根据《联邦食品药品和化妆品法》(Frederal Food…www.healthoo.com|基于30个网页 2. 罕见病药品法 通过《罕见病药品法》(ORPHAN DRUG ACT),使FDA能鼓励治疗罕见病(rare diseases)需要的药品的研究和上市。 198…www.fdc-intl.com|基于23个...
The Orphan Drug Act is not about children without parents. 这个孤儿药法案与失去父母的孩子无关。 The term "orphan drugs" refers to medical products that would not be adopted by major pharmaceutical companies 孤儿药品这个术语是指非主要制药公司生产的药品。 because they serve only a very small por...
The impact of pollination syndrome and habitat on gene flow: a comparative study of two Streptocarpus (Gesneriaceae) species The Orphan Drug Act (ODA) came into effect in 1983 as a solution to meet an unmet need in the industry, Its success is often projected as an example of how... ...
aSorry I was traveling 正在翻译,请等待...[translate] aFor these reasons, in 1983, Congress passed the Orphan Drug Act, 为这些原因, 1983年国会通过了孤儿药物行动,[translate]
This report provides a historical perspective on the characteristics of rare diseases and their treatment and the role of the Orphan Drugs Act of 1983 in advancing rare disease medicines. It also describes the characteristics of orphan drug volumes and p